Kala Bio Inc (KALA)

$7.2

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Kala Bio Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.22M → 70.0K (in $), with an average decrease of 94.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -18.70M → -8.62M (in $), with an average increase of 33.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.5% return, outperforming this stock by 108.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 251.9% return, outperforming this stock by 349.9%

Performance

  • $7.20
    $7.30
    $7.20
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.37%

    Upside

    1.37%

    downward going graph
  • $5.10
    $19.35
    $7.20
    downward going graph

    29.17%

    Downside

    52 Weeks Volatility :73.64%

    Upside

    62.79%

    downward going graph

Returns

PeriodKala Bio IncRussel 2000Index (Russel 2000)
3 Months
-8.28%
0.0%
0.0%
6 Months
-11.87%
0.0%
0.0%
1 Year
-59.64%
-1.5%
-1.5%
3 Years
-97.99%
-20.6%
-20.6%

Highlights

Market Capitalization
19.4M
Book Value
$4.17
Earnings Per Share (EPS)
-22.38
PEG Ratio
0.0
Wall Street Target Price
19.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-33.18%
Return On Equity TTM
-905.22%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
1.3M
EBITDA
-38.7M
Diluted Eps TTM
-22.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-10.17
EPS Estimate Next Year
-11.5
EPS Estimate Current Quarter
-3.62
EPS Estimate Next Quarter
-3.64

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Kala Bio Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 168.47%

Current $7.20
Target $19.33

Technicals Summary

Sell

Neutral

Buy

Kala Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kala Bio Inc
Kala Bio Inc
-5.88%
-11.87%
-59.64%
-97.99%
-98.2%
Moderna, Inc.
Moderna, Inc.
-1.29%
6.96%
-34.5%
-29.77%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.29%
7.75%
8.95%
89.65%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-6.73%
21.9%
48.54%
251.87%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.03%
6.89%
18.96%
83.64%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kala Bio Inc
Kala Bio Inc
11.21
NA
0.0
-10.17
-9.05
-0.33
NA
4.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kala Bio Inc
Kala Bio Inc
Buy
$19.4M
-98.2%
11.21
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Baker Bros Advisors LP

    9.90%
  • Millennium Management LLC

    4.93%
  • Vanguard Group Inc

    1.04%
  • BlackRock Inc

    1.01%
  • Board of Ttees Leland Stanford Jr Univ

    0.78%
  • Geode Capital Management, LLC

    0.69%

Company Information

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.

Organization
Kala Bio Inc
Employees
34
CEO
Mr. Mark T. Iwicki
Industry
Health Technology

FAQs